**Supplementary table 4: Definitions of target volume deviations of other trials**

### CATNON trial

| CATNON trial | Per protocol | Acceptable deviation | Unacceptable deviation |
|--------------|--------------|----------------------|------------------------|
| **GTV** | Hypodense areas on CT (corresponding to T2 or Flair on MRI) included. Plus region of enhancement present on postoperative CT/MRI or the region of enhancement on pre-operative CT/MRI included. Plus tumour resection margin included. | All of the above not fully included. but covered fully by CTV | One or none of the criteria mentioned (T2 area, hypodense area, enhancement) No GTV contoured Not fully contoured/ and potential hypodense areas also not covered by CTV |

| **CTV** | 1.5 - 2 cm volumetric expansion of the GTV is present. Does not extend to contralateral hemisphere when no midline structures like corpus callosum involved. Is not extended into tentorium and meninges by same large margin but a reduced margin of 7-10 mm at these borders | If margin is >1 cm and ≤ 1.4 cm. Extension contralaterally or into skin or into bones without pathologically based evidence or existence of important OAR/sensitive structure within | Margin is < 1 cm Does not cover GTV No CTV present |

| **PTV** | Defined margin based upon known inaccuracy of set-up, around 5-7 mm. 3-D growth algorithm applied (may be reduced towards body border) | Margin less than 3-4 mm | PTV does not cover CTV fully No PTV present |

### EORTC 22042–26042

| Target Volume Delineation | PTV covers all CTV and GTV | GTV and CTV outside the PTV; GTV outside the CTV |
|---------------------------|-----------------------------|--------------------------------------------------|
| **GTV to CTV margin** | 10 mm | 11-15 mm | >15 mm |

### EORTC 22033–26033

(target volume deviations were not predefined, reported were reasons for deviations)

| **GTV** | Region of high signal intensity on T2 or FLAIR–MRI corresponding to the hypodense area on CT, including any areas of CT enhancement; or operative cavity + any residual tumour | Crosses anatomic boundaries Cannot be judged without MRI incorrect | No GTV 2 GTVs |
|--------|-------------------------------------------------------------------------------------------------|-------------------------------------------------|----------------|
| **CTV** | GTV + 1–1.5 cm except at anatomic boundaries where 5 mm is sufficient | Crosses anatomic boundaries Margin incorrect | No CTV; 2 CTVs incorrect |
| **PTV** | CTV + 3D expansion of 5–7 mm | Margin incorrect; Cannot be judged without CTV | 2 PTVs incorrect |

**Supplementary table 4:** Definitions of target volume deviations of other trials

MRI – magnetic resonance imaging; GTV – gross tumor volume; CTV – clinical target volume; PTV – planning target volume

Types of deviation and review criteria in pre-treatment central quality control of tumor bed boost in medulloblastoma – An analysis of the German Radiotherapy Quality Control Panel in the SIOP PNETS MB trial. Strahlentherapie und Radioonkologie. Dietzsch S et al. Department for Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany. Email: stefan.dietzsch@medizin.uni-leipzig.de